In vitro studies suggested that an EGFR blockade could increase sensibility to HER2-targeted agents; however, trials with the EGFR inhibitors gefitinib and cetuximab in patients with breast cancer failed to improve patients’ long-term outcomes [57]. This evidence concerns the gene ERBB2 and breast carcinoma.